LBLennart Brewitz

Lennart Brewitz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lennart Brewitz has a total of 163 co-authors. Here are the top co-authors by number of shared publications:

  • Christopher J. Schofield

    Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK

    36 shared publications
  • Eidarus Salah

    Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK

    21 shared publications
  • Anthony Tumber

    Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK

    19 shared publications
  • Petra Lukacik

    Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot, OX11 0FA, UK

    6 shared publications
  • Yu Nakashima

    Institute of Natural Medicine University of Toyama 2630-Sugitani Toyama 930–0194 Japan

    6 shared publications
  • Amelia Brasnett

    Chemistry Research Laboratory and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK

    5 shared publications

Latest Publications

  • Open Access

    Activity-based proteomics discovery of deubiquitinating enzyme inhibitors with immunomodulatory activity

    by Hannah B. L. Jones, Simeon D. Draganov, Sofia Schönbauer Huamán, Peter A. C. Wing, Chuong Nguyen, Zhu Liang, Julia Dörner, Jasper Lithgow, Emma Murphy, Alice Beard, et al.

    Deubiquitinases (DUBs) play key roles in human pathologies, including cancer, infectious, autoimmune, and neurodegenerative diseases. The progress of potent and selective active site-targeting DUB inhibitors into clinical trials has demonstrated the therapeutic opportunities of such molecules; however, the shared catalytic geometry among DUB family members poses a challenge for achieving inhibitor selectivity. We describe a high-throughput, DUB-focused, activity-based proteomics workflow to identify new types of cysteine-reactive DUB inhibitors. We demonstrate the potential of αβ,α′β′-diepoxyketones (DEKs) and ubiquitin-derived covalently reacting alkynes as the first selective, cell-active compounds targeting USP47, OTUD7B (Cezanne), and USP5. These DUBs are reported to have critical roles in inflammasome formation, hypoxia, and viral replication, respectively. The identified compounds phenocopy these findings, demonstrating the tractability of these DUBs as immunotherapeutic targets.

  • Open Access

    Plant Jumonji-C domain containing 7 proteins catalyze lysine-residue hydroxylation

    by Yicheng Wang, Eleanor Bogie, Anthony Tumber, Konstantin C. Zouboulis, Eidarus Salah, Justin L.P. Benesch, Christopher J. Schofield, Lennart Brewitz

  • Open Access

    Cephalosporins are potent SARS-CoV-2 main protease inhibitors

    by Dorian-Gabriel Muntean, Wojtek Treyde, Dóra Laczi, Stephen M. Laidlaw, Eidarus Salah, Hani Choudhry, Miles W. Carroll, Fernanda Duarte, Christopher J. Schofield, Lennart Brewitz

  • Open Access

    Structural and Functional Validation of Pseudomonas Savastanoi Ethylene Forming Enzymes Reveals Flexibility in 2‐Oxoglutarate Binding Mode and Conformation

    by Yihong Sun, Siddhant Dhingra, Mark D. Allen, Ethan S. Z. Cheng, Zhihong Zhang, Christopher J. Schofield, Lennart Brewitz

    Pseudomonas savastanoi pv. phaseolicola PK2 employs an Fe(II)‐dependent ethylene/succinate‐forming enzyme (PK2 PsEFE) to produce ethylene from 2‐oxoglutarate (2OG). Here we report NMR‐based assays showing that the putative P. savastanoi pv. glycinea PsEFE, which differs from PK2 PsEFE by a single residue, and the P. savastanoi pv.1449B PsEFE, which differs from PK2 PsEFE by 28 residues and a C‐terminal 13‐residue truncation, catalyze ethylene production from 2OG. Like the PK2 PsEFE, they catalyze oxidation of naturally occurring 2OG derivatives to give alcohol and diacid products. Crystallographic analysis demonstrates that the overall fold and active site of 1449B PsEFE is similar to that of PK2 PsEFE. Interestingly, 2OG was observed to adopt an atypical inverse metal ion binding mode in complex with 1449B PsEFE:Mn in which its 2‐oxoacid group is positioned to interact with the guanidinium group of R277, but not the Mn ion, which substitutes for catalytically active Fe(II). Together with reported crystallographic results, this observation indicates that 2OG metal ion binding modes and conformations at the active sites of 2OG oxygenases can vary, possibly in a functionally or disease relevant manner.

  • Open Access

    Structural basis of the promiscuity of the unusual Fe(II) and 2-oxoglutarate dependent human aspartate/asparagine-β-hydroxylase

    by Mariska de Munnik, Amelia Brasnett, Tiankun Zhou, William Myers, Yicheng Wang, Kuntal Chatterjee, Anthony Tumber, Stephen A. Marshall, Philipp S. Simon, Pierre Aller, et al.

    Protein-hydroxylation catalysed by Fe(II) and 2-oxoglutarate (2OG) dependent oxygenases is an important regulatory mechanism in human biology. Such oxygenases typically coordinate their Fe(II) cofactor via a conserved triad of an aspartate- or glutamate- and two histidine-residues. By contrast, aspartate/asparagine β-hydroxylase (AspH), which catalyses asparagine/aspartate-residue oxidation in epidermal growth factor-like domains (EGFDs), has only two histidine-residues (H679, H725), with a water occupying the site normally occupied by an aspartate- or glutamate-residue. We describe mechanistic studies with catalytically active AspH crystals. Turnover studies with single crystals under cryogenic conditions give (3 R )-hydroxylated EGFDs with the product alcohol coordinating Fe(II) trans to H725. Time-resolved serial crystallography of microcrystals using an acoustic droplet ejection system, coupled to X-ray emission analyses, demonstrate turnover within 1.5 s, giving a product complex in which Fe(II) is regenerated. Solution and crystallographic studies with the O 2 surrogate nitric oxide imply O 2 binds to Fe(II) trans to H725. The additional Fe-chelating water is maintained throughout AspH catalysis and is not directly involved in substrate hydroxylation, because O 2 is the sole oxygen source in alcohol products, as shown by 18 O labelling studies. The results reveal how AspH accommodates both aspartate- and asparagine-substrates and will assist in efforts targeting AspH for cancer treatment.


  • Open Access

    Expanding the Alkene‐Forming Capability of the Pseudomonas Savastanoi Ethylene‐Forming Enzyme

    by Siddhant Dhingra, Yihong Sun, Zhihong Zhang, Christopher J. Schofield, Lennart Brewitz

    Ethylene is an established signaling molecule in plants and other organisms; however, the biosynthesis and biological roles of gaseous alkenes other than ethylene are less well defined. The Pseudomonas savastanoi ethylene/succinate‐forming enzyme (PsEFE) catalyzes ethylene production from 2‐oxoglutarate (2OG), though does not catalyze formation of alkenes from C4 alkyl‐ or hydroxyl‐substituted 2OG derivatives. Here we report studies on the reactivity of L206 PsEFE variants with C4‐substituted 2OG derivatives. Spectroscopic evidence reveals that L206V and L206A PsEFE react with C4‐substituted 2OG derivatives to give diacid and alcohol products, similarly to wildtype (wt) PsEFE. Importantly, L206V PsEFE, but not L206A and L206G PsEFE, catalyzed production of low levels of acetaldehyde and propylene from the natural metabolites 4‐hydroxy‐2OG and 4‐methyl‐2OG, respectively. By contrast, L206A PsEFE, but not L206V and L206G PsEFE, catalyzed formation of low levels of 1‐butylene from 4‐ethyl‐2OG. Together with studies from others, the combined results indicate the potential of bump‐and‐hole studies to modify the substrate and product selectivities of PsEFE reactions, provided that the PsEFE variant:2OG derivative pairs are matched. The results suggest that wildtype 2OG oxygenases other than PsEFE may catalyze production of gaseous alkenes other than ethylene.


  • Open Access

    Structural and functional consequences of aspartate/asparagine-β-hydroxylase variants causing Traboulsi syndrome

    by Cynthia X. Hou, Amelia Brasnett, Patrick Rabe, Christopher J. Schofield, Lennart Brewitz


  • Open Access

    Profiling Inhibitor Scaffolds for the Cancer Target Jumonji‐C Domain‐Containing Protein 6

    by Thomas P. Corner, Eidarus Salah, Anthony Tumber, James P. Holt‐Martyn, Lennart Brewitz, Christopher J. Schofield

    The human 2‐oxoglutarate‐dependent oxygenase Jumonji‐C domain‐containing protein 6 (JMJD6) catalyzes post‐translational C‐5 lysyl residue hydroxylation in multiple proteins. Aberrant JMJD6 catalysis is associated with the upregulation of androgen receptor splice variant 7 (AR‐V7), which confers resistance towards antiandrogens used for prostate cancer treatment; JMJD6 is thus a promising cancer target. To date, few small‐molecule JMJD6 inhibitors are reported, likely in part reflecting a lack of robust assays to monitor effects of small molecules on catalysis by isolated JMJD6. The use of solid‐phase extraction coupled to mass spectrometry assays is described to screen scaffolds for the development of selective JMJD6 inhibitors. The results reveal that the reported JMJD6 inhibitors WL12, SKLB325, and Compound 7p manifest relatively inefficient JMJD6 inhibition in vitro. By contrast, some, but not all, clinically used inhibitors of the human hypoxia‐inducible factor‐α prolyl hydroxylase domain‐containing proteins (PHDs) efficiently inhibit isolated JMJD6, in particular Enarodustat and Desidustat. The results identify attractive scaffolds for the development of selective, cell permeable JMJD6 inhibitors and suggest that JMJD6 inhibition is a potential off‐target effect of PHD inhibitors in clinical use.


  • Open Access

    C6-Alkoxy substituted penicillins are potent non-covalently binding inhibitors of the SARS-CoV-2 main protease

    by Dorian-Gabriel Muntean, Wojtek Treyde, Linda Kinena, Eidarus Salah, Hani Choudhry, Fernanda Duarte, Lennart Brewitz, Christopher J. Schofield

    Introduction of a C6-alkoxy group on the penicillin scaffold can alter the mechanism of SARS-CoV-2 main protease (M pro ) inhibition.


  • Open Access

    RaPID discovery of cell-permeable helical peptide inhibitors con-taining cyclic β-amino acids against SARS-CoV-2 main protease

    by Marina Kawai, Tika R. Malla, H. T. Henry Chan, Anthony Tumber, Lennart Brewitz, Eidarus Salah, Naohiro Terasaka, Takayuki Katoh, Akane Kawamura, Christopher J. Schofield, et al.

    The ribosomal synthesis of a helical peptide library containing structurally constrained cyclic β-amino acid at every third position and its application for the RaPID selection against SARS-CoV-2 main protease (Mpro) inhibitors.